Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0OGZEE
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Mirzotamab clezutoclax
|
|||||
| Synonyms |
ABBV-155; ABBV 155; ABBV155
Click to Show/Hide
|
|||||
| Organization |
AbbVie, Inc.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 2 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
Mirzotamab
|
Antibody Info | ||||
| Antigen Name |
CD276 antigen (CD276)
|
Antigen Info | ||||
| Payload Name |
Clezutoclax
|
Payload Info | ||||
| Therapeutic Target |
Bcl-2-like protein 1 (BCL2L1)
|
Target Info | ||||
| Linker Name |
Valine-alanine (cleavable linker)
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
| Combination Type |
clezutoclax
|
|||||
| Puchem SID | ||||||
| ChEBI ID | ||||||
